Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up

Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirzania, Mehrzad, Khalili, Sedigheh, Hasanpoor, Akbar, Shamshiri, Ahmad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003443/
https://www.ncbi.nlm.nih.gov/pubmed/24800039
_version_ 1782313851403894784
author Mirzania, Mehrzad
Khalili, Sedigheh
Hasanpoor, Akbar
Shamshiri, Ahmad Reza
author_facet Mirzania, Mehrzad
Khalili, Sedigheh
Hasanpoor, Akbar
Shamshiri, Ahmad Reza
author_sort Mirzania, Mehrzad
collection PubMed
description Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patient's clinical symptoms and platelet counts improved.
format Online
Article
Text
id pubmed-4003443
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-40034432014-05-05 Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up Mirzania, Mehrzad Khalili, Sedigheh Hasanpoor, Akbar Shamshiri, Ahmad Reza Int J Hematol Oncol Stem Cell Res Case Report Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patient's clinical symptoms and platelet counts improved. Tehran University of Medical Sciences 2014 /pmc/articles/PMC4003443/ /pubmed/24800039 Text en © 2014 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Case Report
Mirzania, Mehrzad
Khalili, Sedigheh
Hasanpoor, Akbar
Shamshiri, Ahmad Reza
Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_full Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_fullStr Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_full_unstemmed Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_short Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_sort anti-cd20 antibody is effective in the patient with refractory amegakaryocytic thrombocytopenia, 25 months follow up
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003443/
https://www.ncbi.nlm.nih.gov/pubmed/24800039
work_keys_str_mv AT mirzaniamehrzad anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup
AT khalilisedigheh anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup
AT hasanpoorakbar anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup
AT shamshiriahmadreza anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup

Ejemplares similares